Sartorius Stedim Biotech S.A. (EPA:DIM)

Market Cap	17.16B -7.5%
Revenue (ttm)	2.98B +4.4%
Net Income	268.10M +31.2%
EPS	2.76 +30.7%
Shares Out	97.30M
PE Ratio	63.94
Forward PE	33.31
Dividend	0.69 (0.39%)
Ex-Dividend Date	Mar 31, 2026

Volume	61,299
Open	176.40
Previous Close	176.40
Day's Range	174.30 - 177.20
52-Week Range	150.00 - 224.00
Beta	1.09
Analysts	Buy
Price Target	232.43 (+31.69%)
Earnings Date	Jul 23, 2026

About Sartorius Stedim Biotech

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides fluid management services; biolayer interferometry instruments; microbiolog...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1978
• Employees: 10,456
• Stock Exchange: Euronext Paris
• Ticker Symbol: DIM

Financial Performance

In 2025, Sartorius Stedim Biotech's revenue was 2.97 billion, an increase of 6.74% compared to the previous year's 2.78 billion. Earnings were 265.60 million, an increase of 51.68%.

Analyst Summary

According to 14 analysts, the average rating for DIM stock is "Buy." The 12-month stock price target is €232.43, which is an increase of 31.69% from the latest price.

Price Target

€232.43

(31.69% upside)

Analyst Consensus: Buy